siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer.

CONCLUSIONS: LNP siRNA can silence target genes in vivo and enable inhibition of traditionally non-druggable genes like CLU and other promising co-targeting approaches in ENZ-R CRPC therapeutics. PMID: 26106075 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26106075?dopt=Abstract

Source: Clinical Cancer Research - June 23, 2015 Category: Cancer & Oncology Authors: Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave ME Tags: Clin Cancer Res Source Type: research